Sign in or create an account to add this stock to your watchlist.
About New England Nuclear (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001
Debt
Debt-to-Equity Ratio7.87
Current Ratio3.51
Quick Ratio2.80
Price-To-Earnings
Trailing P/E Ratio14.55
Forward P/E Ratio16.92
P/E Growth1.42
Sales & Book Value
Annual Sales$331.38 million
Price / Sales1.68
Cash Flow$1.5832 per share
Price / Cash9.19
Book Value$0.88 per share
Price / Book16.53
Profitability
EPS (Most Recent Fiscal Year)$1.00
Net Income$123.38 million
Net Margins38.32%
Return on Equity-145.14%
Return on Assets11.84%
Miscellaneous
Employees483
Outstanding Shares38,280,000
New England Nuclear (NASDAQ:LNTH) Frequently Asked Questions
What is New England Nuclear's stock symbol?
New England Nuclear trades on the NASDAQ under the ticker symbol "LNTH."
How were New England Nuclear's earnings last quarter?
New England Nuclear Co. (NASDAQ:LNTH) released its quarterly earnings results on Wednesday, May, 2nd. The medical equipment provider reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. The medical equipment provider earned $82.63 million during the quarter, compared to the consensus estimate of $81.15 million. New England Nuclear had a net margin of 38.32% and a negative return on equity of 145.14%. The company's revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.11 EPS. View New England Nuclear's Earnings History.
What price target have analysts set for LNTH?
4 brokers have issued 1 year price objectives for New England Nuclear's stock. Their predictions range from $22.00 to $27.00. On average, they anticipate New England Nuclear's share price to reach $24.00 in the next twelve months. View Analyst Ratings for New England Nuclear.
Are investors shorting New England Nuclear?
New England Nuclear saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 666,888 shares, a decrease of 25.7% from the April 30th total of 897,426 shares. Based on an average daily volume of 522,577 shares, the short-interest ratio is currently 1.3 days. Currently, 1.8% of the shares of the company are sold short.
Who are some of New England Nuclear's key competitors?
Some companies that are related to New England Nuclear include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), ARCA biopharma (ABIO), GeneNews (GNWSF) and FluoroPharma Medical (FPMI).
Who are New England Nuclear's key executives?
New England Nuclear's management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 58)
- Mr. John W. Crowley, CFO & Treasurer (Age 54)
- Mr. Michael P. Duffy, Sr. VP of Strategy & Bus. Devel., Gen. Counsel and Sec. (Age 57)
- Mr. Timothy G. Healey, Sr. VP of Commercial (Age 52)
- Mr. William C. Dawes Jr., VP of Manufacturing and Operations (Age 46)
When did New England Nuclear IPO?
(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.
Has New England Nuclear been receiving favorable news coverage?
News articles about LNTH stock have been trending somewhat positive on Sunday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. New England Nuclear earned a news impact score of 0.09 on Accern's scale. They also gave news coverage about the medical equipment provider an impact score of 46.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of New England Nuclear?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is New England Nuclear's stock price today?
One share of LNTH stock can currently be purchased for approximately $14.55.
How big of a company is New England Nuclear?
New England Nuclear has a market capitalization of $556.99 million and generates $331.38 million in revenue each year. The medical equipment provider earns $123.38 million in net income (profit) each year or $1.00 on an earnings per share basis. New England Nuclear employs 483 workers across the globe.
How can I contact New England Nuclear?
New England Nuclear's mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for New England Nuclear (LNTH)
MarketBeat's community ratings are surveys of what our community members think about New England Nuclear and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
New England Nuclear (NASDAQ:LNTH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for New England Nuclear in the last 12 months. Their average twelve-month price target is $24.00, suggesting that the stock has a possible upside of 64.95%. The high price target for LNTH is $27.00 and the low price target for LNTH is $22.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.00 | $24.00 | $24.00 | $24.00 |
| Price Target Upside: | 64.95% upside | 6.19% upside | 6.19% upside | 6.19% upside |
New England Nuclear (NASDAQ:LNTH) Consensus Price Target History
New England Nuclear (NASDAQ:LNTH) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
New England Nuclear (NASDAQ:LNTH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
New England Nuclear (NASDAQ LNTH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 92.51%
New England Nuclear (NASDAQ LNTH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/30/2018 | Cesare Orlandi | Insider | Sell | 8,801 | $18.00 | $158,418.00 | 97,216 |  |
| 4/26/2018 | Cesare Orlandi | Insider | Sell | 4,194 | $18.00 | $75,492.00 | 108,311 | |
| 4/3/2018 | Michael P Duffy | Insider | Sell | 27,313 | $15.30 | $417,888.90 | 191,472 | |
| 3/14/2018 | Michael P Duffy | Insider | Sell | 11,492 | $16.60 | $190,767.20 | | |
| 2/26/2018 | Timothy G Healey | SVP | Sell | 3,696 | $19.58 | $72,367.68 | 64,582 | |
| 1/16/2018 | John W Crowley | CFO | Sell | 3,866 | $23.52 | $90,928.32 | | |
| 1/10/2018 | Michael P Duffy | Insider | Sell | 21,655 | $22.40 | $485,072.00 | 156,784 | |
| 11/17/2017 | Timothy G Healey | SVP | Sell | 11,314 | $21.51 | $243,364.14 | | |
| 11/14/2017 | Michael P Duffy | Insider | Sell | 11,917 | $21.63 | $257,764.71 | 152,301 | |
| 10/13/2017 | John W Crowley | CFO | Sell | 6,755 | $18.41 | $124,359.55 | | |
| 9/13/2017 | Derace L Schaffer | Director | Sell | 15,000 | $17.50 | $262,500.00 | 48,730 | |
| 9/11/2017 | Michael P Duffy | Insider | Sell | 20,000 | $16.45 | $329,000.00 | 184,218 | |
| 9/7/2017 | David F Burgstahler | Director | Sell | 102,958 | $16.56 | $1,704,984.48 | 13,248 | |
| 9/6/2017 | David F Burgstahler | Director | Sell | 78,833 | $16.95 | $1,336,219.35 | 13,248 | |
| 9/5/2017 | Cesare Orlandi | Insider | Sell | 18,000 | $16.69 | $300,420.00 | 87,078 | |
| 9/5/2017 | David F Burgstahler | Director | Sell | 52,010 | $17.08 | $888,330.80 | 13,248 | |
| 9/1/2017 | David F Burgstahler | Director | Sell | 6,000 | $17.10 | $102,600.00 | 13,248 | |
| 8/31/2017 | David F Burgstahler | Director | Sell | 230,685 | $17.25 | $3,979,316.25 | 13,248 | |
| 8/28/2017 | David F Burgstahler | Director | Sell | 91,166 | $17.01 | $1,550,733.66 | 13,248 | |
| 8/16/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 12,128 | $17.05 | $206,782.40 | | |
| 8/16/2017 | David F Burgstahler | Director | Sell | 140,846 | $17.27 | $2,432,410.42 | 13,248 | |
| 8/15/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 40,779 | $17.06 | $695,689.74 | | |
| 8/14/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 87,939 | $17.40 | $1,530,138.60 | | |
| 7/12/2017 | Mary Anne Heino | CEO | Sell | 10,000 | $18.05 | $180,500.00 | 592,468 | |
| 6/20/2017 | David F Burgstahler | Director | Sell | 3,000,000 | $14.87 | $44,610,000.00 | | |
| 6/12/2017 | Mary Anne Heino | CEO | Sell | 10,000 | $15.39 | $153,900.00 | 602,468 | |
| 6/12/2017 | Michael P Duffy | Insider | Sell | 20,000 | $15.42 | $308,400.00 | 188,234 | |
| 5/10/2017 | Derace L Schaffer | Director | Sell | 10,000 | $15.75 | $157,500.00 | 63,730 | |
| 5/9/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 3,000,000 | $13.40 | $40,200,000.00 | | |
| 5/9/2017 | Derace L Schaffer | Director | Sell | 10,000 | $14.75 | $147,500.00 | 73,730 | |
| 3/17/2017 | David F Burgstahler | Director | Sell | 3,000,000 | $12.20 | $36,600,000.00 | | |
| 11/21/2016 | David F Burgstahler | Director | Sell | 2,500,000 | $9.00 | $22,500,000.00 | | |
(Data available from 1/1/2013 forward)
New England Nuclear (NASDAQ LNTH) News Headlines
| Source: |
|
New England Nuclear (NASDAQ:LNTH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
New England Nuclear (NASDAQ:LNTH) Income Statement, Balance Sheet and Cash Flow Statement
New England Nuclear (NASDAQ LNTH) Stock Chart for Sunday, May, 27, 2018
Loading chart…
